<DOC>
	<DOCNO>NCT00019435</DOCNO>
	<brief_summary>RATIONALE : The LMB-9 immunotoxin may able locate tumor cell kill without harm normal cell . This may effective treatment advance solid tumor . PURPOSE : Phase I trial study effectiveness LMB-9 immunotoxin treat patient advance solid tumor respond standard therapy .</brief_summary>
	<brief_title>LMB-9 Immunotoxin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect pharmacokinetics LMB-9 immunotoxin patient advance solid tumor express Lewis Y antigen . II . Evaluate anti-tumor activity immunogenicity treatment regimen patient . OUTLINE : This dose-escalation study . Patients receive LMB-9 immunotoxin IV 30 minute day 1 , 3 , 5 . Patients negative neutralizing antibody LMB-9 immunotoxin stable respond disease receive additional course every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos LMB-9 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional cohort 6 patient may treat MTD . Patients follow 1 month every 2 month thereafter . PROJECTED ACCRUAL : Approximately 20-30 patient accrue within 12-24 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor refractory standard treatment effective standard therapy exist Bladder cancer Breast cancer Colon cancer Esophageal cancer Gastric cancer Nonsmall cell lung cancer Pancreatic cancer Evaluable measurable disease B3 antigen present 30 % tumor cell No prior concurrent CNS metastasis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : Granulocyte count great 1,200/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin normal SGOT/SGPT le 5 time upper limit normal Albumin least 3.0 g/dL No history liver disease No positive hepatitis B C antigen Renal : Creatinine great 1.4 mg/dL Cardiovascular : No history coronary artery disease No New York Association class IIIV heart disease No arrhythmia require treatment No contraindication pressor therapy Pulmonary : FEV1 FVC great 65 % predict value Pulmonary function test require patient significant smoke history possible pulmonary disease Other : No active peptic ulcer disease No known allergy omeprazole No history seizure disorder No concurrent malignancy No concurrent medical psychiatric condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosourea ) recover Endocrine therapy : At least 3 week since prior hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>